Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation

Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation

Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human epidermal growth factor receptor 2 positive (HER2+) breast cancer who receive neoadjuvant “docetaxel / carboplatin / trastuzumab + pertuzumab” regim...

Full description

Saved in:
Bibliographic Details
Main Authors: M. V. Zhuravleva, K. A. Kokushkin, E. A. Luchinin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, L. G. Zhukova
Format: Article
Language:Russian
Published: IRBIS LLC 2024-02-01
Series:Фармакоэкономика
Subjects:
breast cancer
neoadjuvant therapy
neutropenia
empegfilgrastim
filgrastim
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/946
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmacoeconomics.ru/jour/article/view/946

Similar Items